OBSIDIAN THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
OBSIDIAN THERAPEUTICS, INC. (OBX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 243.61 million shares for the 6-month period ending 2026-06-30, per its S-1 filed 2026-08-28.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-28
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|
| 2026-06-30 | 243.61M shares S-1 · filed 2026-08-28 | |
| 2025-12-31 | 253.12M shares S-1 · filed 2026-08-28 | |
| 2025-06-30 | 254.31M shares S-1 · filed 2026-08-28 | |
| 2024-12-31 | 255.69M shares S-1 · filed 2026-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |